| NCT06816992 | ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC | RECRUITING | PHASE1 | 2025-02-27 | 2027-05 | 2026-05 |
| NCT06012721 | Effect of Food on the Pharmacokinetics of ORIC-114 | COMPLETED | PHASE1 | 2023-09-11 | 2023-11-23 | 2023-11-23 |
| NCT05413421 | Study of ORIC-944 in Patients With Metastatic Prostate Cancer | RECRUITING | PHASE1 | 2022-06-01 | 2026-09 | 2025-12 |
| NCT05315700 | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | RECRUITING | PHASE1, PHASE2 | 2022-03-10 | 2027-09 | 2026-09 |
| NCT05227144 | Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma | COMPLETED | PHASE1 | 2022-01-06 | 2025-03-03 | 2025-03-03 |
| NCT04033328 | Study of ORIC-101 in Combination With Enzalutamide | TERMINATED | PHASE1 | 2019-10-28 | 2023-12-04 | 2022-11-22 |
| NCT03928314 | Study of ORIC-101 in Combination With Anticancer Therapy | TERMINATED | PHASE1 | 2019-05-02 | 2023-12-04 | 2022-09-22 |
| NCT03835637 | Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects | COMPLETED | PHASE1 | 2018-03-23 | 2018-07-04 | 2018-07-04 |
| NCT03324555 | Study of ORIC-101 in Healthy Adult Subjects | COMPLETED | PHASE1 | 2017-10-19 | 2017-12-18 | 2017-12-18 |